Treatment of tuberculosis with levofloxacin or moxifloxacin: Report of 6 pediatric cases

Pediatric Infectious Disease Journal

Volumn 31, Issue 12, 2012, Pages 1309-1311

  Chauny, Jean Vannak ^a,b   Lorrot, Mathie ^a,c   Prot Labarthe, Sonia ^a   De Lauzanne, Agathe ^a   Doit, Catherine ^a   Géréral, Tina ^a,b   Bourdon, Olivier ^a,b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Fluoroquinolones; Levofloxacin; Moxifloxacin; Multidrug resistant tuberculosis; Pediatrics

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; ADVERSE OUTCOME; ARTHRALGIA; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FRANCE; HUMAN; INFANT; MALE; MYCOBACTERIUM TUBERCULOSIS; POLYARTHRITIS; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNIVERSITY HOSPITAL;

ADOLESCENT; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; CHILD; CHILD, PRESCHOOL; FEMALE; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; INFANT; MALE; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; QUINOLINES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84870920646     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318269cc6a     Document Type: Article

References (10)

1. Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis-critical steps for prevention and control. N Engl J Med. 2010;363:1050-1058.
2. Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10:621-629.
3. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008;359:563-574.
4. Bradley JS, Jackson MA; Committee on Infectious Diseases; American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics. 2011;128:e1034-e1045.
5. World Health Organization. Rapid Advice: Treatment of Tuberculosis in Children. Geneva, Switzerland: WHO Press. WHO/HTM/TB/2010.13. Available at: http://whqlibdoc.who.int/publications/2010/9789241500449-eng.pdf. Accessed February 17, 2012.
6. Al-Dabbagh M, Lapphra K, McGloin R, et al. Drug-resistant tuberculosis: pediatric guidelines. Pediatr Infect Dis J. 2011;30:501-505.
7. Seddon JA, Hesseling AC, Marais BJ, et al. Paediatric use of second-line anti-tuberculosis agents: a review. Tuberculosis (Edinb). 2012;92:9-17.
8. Ettehad D, Schaaf HS, Seddon JA, et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:449-456.
9. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis J. 1997;16:127-129; discussion 160.
10. Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J. 2007;26:879-891.